# Journal of Thoracic Oncology

Source: https://onco.cc/journals/journal-of-thoracic-oncology/  
OnCo record `journal-of-thoracic-oncology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Journal of Thoracic Oncology is the IASLC's journal and the leading specialist venue for lung cancer and mesothelioma: staging, biomarkers, targeted-therapy and screening research.

## Summary

Publishes the IASLC TNM staging proposals, lung-cancer screening implementation studies, biomarker testing guidelines and phase 2 trials and long-term follow-up in EGFR, ALK, KRAS and other molecularly defined lung cancers. Hybrid access via Elsevier; the World Conference on Lung Cancer abstracts appear here.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JTO; J Thorac Oncol
- Publisher: Elsevier
- Scope: thoracic oncology
- Access: hybrid

## Sources

- IASLC: https://www.iaslc.org

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- key papers: [ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer](https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/), [Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study](https://onco.cc/key-papers/paper-nct06015503-j-thorac-oncol-2026/), [Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://onco.cc/key-papers/paper-camidge-j-thorac-oncol/), [Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial](https://onco.cc/key-papers/paper-camel-j-thorac-oncol-2023-update/), [CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report](https://onco.cc/key-papers/paper-nct03381274-j-thorac-oncol-2023/), [Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes](https://onco.cc/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/), [D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results](https://onco.cc/key-papers/paper-li-j-thorac-oncol/), [Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial](https://onco.cc/key-papers/paper-nct05955391-j-thorac-oncol-2026/), [Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status](https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/), [Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study](https://onco.cc/key-papers/paper-nct03775486-j-thorac-oncol-2023/), [Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study](https://onco.cc/key-papers/paper-nct03003962-j-thorac-oncol-2025/), [Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study](https://onco.cc/key-papers/paper-zhou-j-thorac-oncol/), [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://onco.cc/key-papers/paper-orient-11-j-thorac-oncol-2020/), [Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial](https://onco.cc/key-papers/paper-nct06120140-j-thorac-oncol-2025/), [Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC](https://onco.cc/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/), [First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study](https://onco.cc/key-papers/paper-nct05186974-j-thorac-oncol-2026/), [Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)](https://onco.cc/key-papers/paper-kozono-j-thorac-oncol/), [PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project](https://onco.cc/key-papers/paper-hirsch-j-thorac-oncol/), [PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project](https://onco.cc/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/), [Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report](https://onco.cc/key-papers/paper-nct05663866-j-thorac-oncol-2025/), [RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC](https://onco.cc/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/), [SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization](https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/), [SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China](https://onco.cc/key-papers/paper-nct04665856-j-thorac-oncol-2026/), [Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial](https://onco.cc/key-papers/paper-nct05168566-j-thorac-oncol-2026/), [SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)](https://onco.cc/key-papers/paper-lung-map-j-thorac-oncol-2019/), [The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours](https://onco.cc/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/), [Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report](https://onco.cc/key-papers/paper-pharos-j-thorac-oncol-2025/), [Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors](https://onco.cc/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/)
- people: [Corinne Faivre-Finn](https://onco.cc/people/corinne-faivre-finn/), [Simron Singh](https://onco.cc/people/simron-singh/), [Valerie W. Rusch](https://onco.cc/people/valerie-rusch/)

---
JSON: https://onco.cc/api/v1/entities/journal-of-thoracic-oncology.json